What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GIP/GLP incretin co-formulation · metabolic research blend
Overview
PeptideXpo's Retatrutide + Tirzepatide blend is a single-vial research co-formulation holding 20 mg of retatrutide alongside 40 mg of tirzepatide. Retatrutide (LY3437943) is a triple incretin agonist that engages the GLP-1, GIP, and glucagon receptors; tirzepatide (LY3298176) is a dual GIP/GLP-1 agonist. Each is an incretin-mimetic peptide backed by its own substantial clinical dataset — but the fixed-ratio pairing is a formulation convenience for research only, has never been evaluated as a combination product in a dedicated clinical trial, and should not be assumed to have any pharmacology beyond the additive behavior of its two well-characterized components. PeptideXpo supplies the blend as a lyophilized powder with per-component analytical documentation: the batch COA reports each peptide's identity and RP-HPLC purity plus the verified fill ratio, rather than a single combined purity figure — the correct way to release a two-active blend. Buyers who need to vary the ratio, or who want the two peptides as separate vials, should order the single-component SKUs instead. Supplied for research use only, not for human or veterinary use.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Research-use-only reference material; not for human or veterinary use. The fixed combination is not a clinically validated product.
Frequently asked questions
No. Retatrutide and tirzepatide each have their own independent clinical development programs and datasets, but the fixed-ratio combination of the two has not been evaluated in a dedicated clinical trial. This blend is a research formulation only; any expectation of its behavior should be limited to the additive pharmacology of the two individually characterized components, and it should not be treated as a validated combination product.
A blend containing two distinct actives is released against per-component analytics, not a single combined number. PeptideXpo's COA for this SKU reports the identity and RP-HPLC purity of each peptide separately, along with the verified fill ratio (20 mg retatrutide + 40 mg tirzepatide). A single 'blend purity' figure would be meaningless for a two-component product, so the per-component breakdown is the meaningful release record.
Related peptides
